Timothy Eley

4.4k total citations · 1 hit paper
52 papers, 1.8k citations indexed

About

Timothy Eley is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Timothy Eley has authored 52 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hepatology, 28 papers in Infectious Diseases and 26 papers in Epidemiology. Recurrent topics in Timothy Eley's work include Hepatitis C virus research (34 papers), HIV/AIDS drug development and treatment (25 papers) and Liver Disease Diagnosis and Treatment (19 papers). Timothy Eley is often cited by papers focused on Hepatitis C virus research (34 papers), HIV/AIDS drug development and treatment (25 papers) and Liver Disease Diagnosis and Treatment (19 papers). Timothy Eley collaborates with scholars based in United States, Germany and Sweden. Timothy Eley's co-authors include Richard Bertz, Fiona McPhee, David Gardiner, Dennis M. Grasela, C Pasquinelli, Megan Wind‐Rotolo, Anna Persson, Anna S. Lok, Eric Lawitz and Gregory T. Everson and has published in prestigious journals such as New England Journal of Medicine, Hepatology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Timothy Eley

52 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

2012 454 citations Anna S. Lok, David Gardiner et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy Eley United States	21	1.3k	1.1k	704	161	151	52	1.8k
Hartwig Klinker Germany	31	1.3k 1.0×	1.6k 1.5×	1.1k 1.6×	279 1.7×	122 0.8×	157	2.9k
Eugenia Vispo Spain	31	1.9k 1.4×	1.8k 1.6×	1.1k 1.6×	173 1.1×	167 1.1×	104	2.9k
Pablo Labarga Spain	36	2.1k 1.6×	2.2k 2.0×	2.0k 2.8×	160 1.0×	130 0.9×	137	3.8k
Monika Peeters Belgium	33	2.3k 1.8×	2.3k 2.2×	2.5k 3.5×	253 1.6×	219 1.5×	64	4.2k
Anu Osinusi United States	23	1.6k 1.2×	1.4k 1.2×	618 0.9×	117 0.7×	137 0.9×	86	2.0k
Marina Núñez Spain	33	2.3k 1.8×	2.3k 2.1×	1.5k 2.1×	85 0.5×	65 0.4×	104	3.4k
Vanitha Sekar United States	19	613 0.5×	633 0.6×	954 1.4×	50 0.3×	78 0.5×	33	1.5k
Rolf van Heeswijk United States	17	644 0.5×	930 0.9×	815 1.2×	218 1.4×	63 0.4×	27	1.5k
Bach-Yen Nguyen United States	12	793 0.6×	720 0.7×	1.6k 2.3×	240 1.5×	64 0.4×	13	2.2k
Maria Beumont United States	22	1.1k 0.9×	1.2k 1.1×	775 1.1×	73 0.5×	124 0.8×	55	1.8k

Countries citing papers authored by Timothy Eley

Since Specialization

Citations

This map shows the geographic impact of Timothy Eley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Eley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Eley more than expected).

Fields of papers citing papers by Timothy Eley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Eley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Eley. The network helps show where Timothy Eley may publish in the future.

Co-authorship network of co-authors of Timothy Eley

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Eley. A scholar is included among the top collaborators of Timothy Eley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Eley. Timothy Eley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yuen, Man‐Fung, Elina Berliba, Wattana Sukeepaisarnjaroen, et al.. (2022). Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B. Hepatology Communications. 6(12). 3457–3472. 17 indexed citations

Gandhi, Yash, Timothy Eley, Aberra Fura, et al.. (2018). Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clinical Pharmacokinetics. 57(8). 911–928. 40 indexed citations

Zhu, Li, Hanbin Li, Phyllis Chan, et al.. (2018). Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. Infectious Diseases and Therapy. 7(2). 261–275. 4 indexed citations

Garimella, Τushar, Xiaolu Tao, Karen Sims, et al.. (2017). Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects. Drugs in R&D. 18(1). 55–65. 20 indexed citations

Chan, Phyllis, Hanbin Li, Li Zhu, et al.. (2017). Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. Clinical Pharmacokinetics. 56(10). 1173–1183. 11 indexed citations

Ross, Lisa, Ivy Song, Niki Arya, et al.. (2016). No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects. BMC Infectious Diseases. 16(1). 347–347. 5 indexed citations

Garimella, Τushar, Xiaoli You, Shu‐Pang Huang, et al.. (2016). A Review of Daclatasvir Drug–Drug Interactions. Advances in Therapy. 33(11). 1867–1884. 21 indexed citations

Gong, Jiachang, Timothy Eley, Bing He, et al.. (2015). Characterization of ADME properties of [¹⁴C]asunaprevir (BMS-650032) in humans. Xenobiotica. 46(1). 52–64. 13 indexed citations

Kandoussi, Hamza, Hao Jiang, Jianing Zeng, et al.. (2015). A highly sensitive and selective LC–MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis. 119. 145–151. 7 indexed citations

10.

Pandey, Preetanshu, Dilbir S. Bindra, Neil Mathias, et al.. (2014). From Bench to Humans: Formulation Development of a Poorly Water Soluble Drug to Mitigate Food Effect. AAPS PharmSciTech. 15(2). 407–416. 21 indexed citations

11.

Bronowicki, Jean–Pierre, Vlad Ratziu, Adrián Gadano, et al.. (2014). Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology. 61(6). 1220–1227. 21 indexed citations

12.

Eley, Timothy, Shu‐Pang Huang, Bing He, et al.. (2014). The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus. Clinical Drug Investigation. 34(9). 661–671. 17 indexed citations

13.

Bronowicki, J.‐P., Vlad Ratziu, Adrián Gadano, et al.. (2013). 1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016). Journal of Hepatology. 58. S571–S572. 10 indexed citations

14.

Lok, Anna S., David Gardiner, Christophe Hézode, et al.. (2013). Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. Journal of Hepatology. 60(3). 490–499. 111 indexed citations

15.

McPhee, Fiona, Dennis Hernandez, Fei Yu, et al.. (2013). Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir And Asunaprevir. Hepatology. 58(3). 902–911. 98 indexed citations

16.

Eley, Timothy, Shu‐Pang Huang, Francesca Conradie, et al.. (2013). Clinical and Pharmacogenetic Factors Affecting Neonatal Bilirubinemia Following Atazanavir Treatment of Mothers During Pregnancy. AIDS Research and Human Retroviruses. 29(10). 1287–1292. 4 indexed citations

17.

Suzuki, Yoshiyuki, Kenji Ikeda, Fumitaka Suzuki, et al.. (2012). Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Journal of Hepatology. 58(4). 655–662. 179 indexed citations

18.

Lok, Anna S., David Gardiner, Eric Lawitz, et al.. (2012). Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. New England Journal of Medicine. 366(3). 216–224. 454 indexed citations breakdown →

19.

Zhu, Li, Sih‐Han Liao, Michael Child, et al.. (2011). Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. Journal of Antimicrobial Chemotherapy. 67(2). 465–468. 17 indexed citations

20.

Eley, Timothy, Feng Luo, Shruti Agrawal, et al.. (2009). Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects. The Journal of Clinical Pharmacology. 49(6). 700–709. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact